Why the study?
Does the continuation of antiplatelet agents compared to their cessation affect the risk of haemorrhage and thrombosis in patients undergoing ENT surgery?
Does the continuation of antiplatelet agents compared to their cessation affect the risk of haemorrhage and thrombosis in patients undergoing ENT surgery?
Peri-operative management of antiplatelet agents in ENT surgery requires multidisciplinary consultation, as premature cessation carries significant morbidity and mortality risks while continuation may only marginally increase blood loss.
No takes yet. Share an insight, caveat, or question.
May warrant multidisciplinary consultation for antiplatelet management in ENT surgery; leaves open need for prospective trials.
Sylvester et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: